9001cc½ðɳ

English

9001cc½ðɳÉúÎïѪ˨ËÄÏî | ¾«×¼·¢Á¦£¬£¬£¬£¬£¬£¬£¬£¬»¤º½Ôвú¸¾³öÄýѪ¼ì²â

°ä²¼ÓÚ£º2025-01-06

ÎÄÕÂÆðÔ´£º[ÖÐÎÄ]9001cc½ðɳÉúÎï



01

Ôвú¸¾ÑªË¨ÐÔ¼²²¡½ü¿ö


ƾ¾ÝWHO·ÖÎö£¬£¬£¬£¬£¬£¬£¬£¬ÔÚÅ¹ú¶ÈÓë·¢Õ¹Öйú¶È£¬£¬£¬£¬£¬£¬£¬£¬Ôвú¸¾ËÀÓÉÓÚѪ˨˨ÈûÐÔ¼²²¡µÄÕ¼3.1%~13.8% ¡£¡£¡£¡£¡£Ôи¾×÷ÎªÌØÊâÈËȺ£¬£¬£¬£¬£¬£¬£¬£¬ÓÉÓÚ»³Ì¥ÆÚ´ÆÔм¤ËصÄÔö³¤£¬£¬£¬£¬£¬£¬£¬£¬»úÌåÔ­ÓÐÄýѪºÍÏËÈÜϵͳµÄƽºâ±»Í»ÆÆ£¬£¬£¬£¬£¬£¬£¬£¬ÍƽøÁË»³Ì¥ÆÚѪ˨ǰ״̬£¨Ò×˨֢£©ºÍѪ˨ÐÔ²¢·¢Ö¢µÄ²úÉú ¡£¡£¡£¡£¡£ÄýѪºÍÏËÈÜϵͳÒì³£¿£¿£¿£¿ £¿£¿£¿ £¿ÉÄܵ¼ÖÂÔи¾²úÉú¾²ÂöѪ˨˨ÈûÖ¢£¨VTE£©µÄ·çÏÕ±Èͨ³£ÈËȺ¸ß50±¶£¬£¬£¬£¬£¬£¬£¬£¬VTEÒѳÉΪÊÀ½çÁìÓòÄÚÔÓ×¢²ú¸¾µÄµÚ¶þËÀÒòÉõÖÁÉÙÊýÅ¹ú¶ÈµÄµÚÒ»ËÀÒò ¡£¡£¡£¡£¡£Éî¾²ÂöѪ˨(DVT)²»¼°Ê¹ØïÖΣ¬£¬£¬£¬£¬£¬£¬£¬15%¡«24%·¢Õ¹Îª·Î˨Èû(PE)£»£»£»£»£»66%µÄÔвú¸¾ÔÚPE²úÉúµÄ30minÄÚéæÃü ¡£¡£¡£¡£¡£



02

Ôвú¸¾³öÄýѪ¼ì²â½ü¿ö


³öÄýѪ¼ì²âÊÇÆÀ¹À»³Ì¥ÆÚºÍÁÙÝêÆÚ¸¾Å®ÑªÒºÄý¹ÌÖ°ÄÜ״̬µÄ³ÁÒª¼¿Á©£¬£¬£¬£¬£¬£¬£¬£¬ÕâÓÐÖúÓÚ¼ø±ðºÍÖÎÀíDZÔÚµÄÄýѪÒì³££¬£¬£¬£¬£¬£¬£¬£¬ÓÈÆäÊÇÔڸ߷çÏÕ»³Ì¥¡¢²úºó³öѪÒÔ¼°ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪ(DIC)µÈ²¢·¢Ö¢µÄÇé¿öÏ ¡£¡£¡£¡£¡£½üÄê×êÑнøÕ¹¿ì¡¢ÁÙ´²Áìµ¼Òâ˼ǿµÄÐÂÐÍÄýѪ·Ö×Ó±êÖ¾ÎïÔ̺¬ÄýѪø-¿¹ÄýѪø¸´ºÏÎï(thrombin-antithrombin compex£¬£¬£¬£¬£¬£¬£¬£¬TAT)¡¢ÏËÈÜø-¿¹ÏËÈÜø¸´ºÏÎï(plasmin antiplasmincomplex£¬£¬£¬£¬£¬£¬£¬£¬PIC)¡¢×éÖ¯ÐÍÏËÈÜøԭ¼¤»îÎï-ÏËÈÜøԭ¼¤»îÒÖÔìÎï-1¸´ºÏÎï(tissue plasminogen activator-plasminogen activator inhibitor-l complex£¬£¬£¬£¬£¬£¬£¬£¬t-PAIC)¼°ÑªË¨µ÷½Úµ°°×(thrombomodulin£¬£¬£¬£¬£¬£¬£¬£¬TM)£¬£¬£¬£¬£¬£¬£¬£¬¼ò³ÆÐÂѪ˨ËÄÏ£¬£¬£¬£¬£¬£¬£¬ÔÚ²ú¿ÆVTEÔçÆÚÕï¶Ï¡¢¸´·¢ÐÔÁ÷²ú(RSA)µÈ²ú¿ÆÓйØÑªË¨¼²²¡ÖÐÓµÓгÁÒªÁÙ´²ÀûÓüÛÖµ ¡£¡£¡£¡£¡£





9001cc½ðɳÉúÎïÐÂѪ˨ËÄÏîÒÑ»ñµÃ×¢²áÖ¤£¬£¬£¬£¬£¬£¬£¬£¬ÎªÔвú¸¾³öÄýѪ¼ì²âÌṩǿÁ¦Ö§³Ö£¡



03

ÐÂѪ˨ËÄÏîÖúÁ¦Ôвú¸¾VTEÔçÕïÔçÖÎ


ΪÁ˽µµÍ²úǰºÍ²úºó³öѪµÄ·çÏÕ£¬£¬£¬£¬£¬£¬£¬£¬²¢ÔÚ»³Ì¥ºÍÁÙÝêÆÚ¼äά³ÖÌ¥ÅÌÖ°ÄÜ£¬£¬£¬£¬£¬£¬£¬£¬ÉúÀí¸ßÄý״̬Åã°é×ÅÕû¸ö»³Ì¥¹¦·ò£¬£¬£¬£¬£¬£¬£¬£¬È»¶ø¹ý¶ÈµÄ¸ßÄý״̬¼«Òײ¢·¢»³Ì¥ÆÚVTE ¡£¡£¡£¡£¡£Éò„µÈ×êÑÐÅú×¢CapriniÆÀ·ÖÓë¾²ÂöѪ½¬TM¡¢TAT¡¢t-PAIC¡¢PICˮƽ¶ÔÆÊ¹¬²úÊõºóDVTÐγɷçÏÕÓнϺõÄÔ¤²â¼ÛÖµ£¬£¬£¬£¬£¬£¬£¬£¬ÌáÐÑÁÙ´²¿Éƾ¾ÝÐÂѪ˨ËÄÏîˮƽÔçÆÚ²ÉÈ¡´ëʩԤ·ÀÊõºóDVTµÄ²úÉú ¡£¡£¡£¡£¡£ÍõÓîµÈ×êÑÐÅú×¢TM¡¢TAT¡¢t-PAIC¡¢PICΪӰÏìÔÐÖÐÍíDVT²úÉúµÄ¶ÀÁ¢Ô¤²âÒò×Ó£¬£¬£¬£¬£¬£¬£¬£¬ÐÂѪ˨ËÄÏî½áºÏ¼ì²â¶ÔÔÐÖÐÍíÆÚÔи¾²úÉúDVTµÄÔ¤²â¼ÛÖµÏÔÖøÓÅÓÚ¸÷µ¥ÏîÖ¸±ê¼ì²â»òÁ½Á½½áºÏ£¨P£¼0.05£©£¬£¬£¬£¬£¬£¬£¬£¬ÌáÐѽáºÏ¼ì²â¿ÉΪÁÙ´²ÔçÆÚÕïÖÎÌṩ²Î¿¼£¬£¬£¬£¬£¬£¬£¬£¬¼ûÏÂ±í ¡£¡£¡£¡£¡£




04

ÐÂѪ˨ËÄÏîÖúÁ¦¸´·¢ÐÔÁ÷²ú²¡Òòɸ²é


RSAÊÇÖ¸ÓëͳһÐÔ°éÂÂÂ½Ðø²úÉú¡Ý3´ÎµÄÌìÈ»Á÷²ú£¬£¬£¬£¬£¬£¬£¬£¬²¢ÇÒÿ´ÎÁ÷²ú³£²úÉúÔÚͳһÔÐÁä ¡£¡£¡£¡£¡£ÑªÒº¸ßÄý״̬£¬£¬£¬£¬£¬£¬£¬£¬Ò²½ÐѪ˨ǰ״̬(PTS)£¬£¬£¬£¬£¬£¬£¬£¬Êǵ¼ÖÂRSAµÄ³£¼ûÔ­Òò£¬£¬£¬£¬£¬£¬£¬£¬PTS»áÔÚÌ¥Å̲¿Î»ÐγÉ΢Ѫ˨£¬£¬£¬£¬£¬£¬£¬£¬ÒýÆðÅßÌ¥»òÌ¥¶ùȱѪȱÑõ£¬£¬£¬£¬£¬£¬£¬£¬×îÖÕµ¼ÖÂÁ÷²ú ¡£¡£¡£¡£¡£


ÐÂѪ˨±êÖ¾Îï¶ÔPTSÓгÁÒªÌáÐÑÒâ˼£¬£¬£¬£¬£¬£¬£¬£¬¡¶¸´·¢ÐÔÁ÷²ú¹é²¢ÑªË¨Ç°×´Ì¬ÕïÖÎÖйúר¼Ò¹²Ê¶(2021)¡·ÖÐÖ¸³ö¶ÔÓÚRSA¹é²¢PTS»¼Õß½øÐÐÄýѪְÄܵÄɸ²é£¬£¬£¬£¬£¬£¬£¬£¬³ýPT¡¢APTTµÈ³£ÓÃÖ¸±ê±í£¬£¬£¬£¬£¬£¬£¬£¬ÓÐǰÌáÕ߿ɷ¢Õ¹TAT¡¢TM¡¢PICµÈ·Ö×Ó±êÖ¾Î£¬£¬£¬£¬£¬£¬£¬ÒÔÆÀ¼Û»¼ÕßÌåÄÚÄýѪְÄܼ°Ñª¹ÜÄÚÆ¤Çé¿ö£¬£¬£¬£¬£¬£¬£¬£¬Èçͼ1Ëùʾ ¡£¡£¡£¡£¡£¡¶¸´·¢ÐÔÁ÷²ú²¡Òò²é³­×¨¼Ò¹²Ê¶(2022)¡·Öн¨ÒéÓÐǰÌáÕ߿ɷ¢Õ¹ÐÂѪ˨4Ïî(TM¡¢TAT¡¢t-PAIC¡¢PIC)¼ì²â ¡£¡£¡£¡£¡£


ͼ1?¸´·¢ÐÔÁ÷²úPTSÆÀ¹Àɸ²éÁ÷³Ì

ÆðÔ´£º¡¶¸´·¢ÐÔÁ÷²ú¹é²¢ÑªË¨Ç°×´Ì¬ÕïÖÎÖйúר¼Ò¹²Ê¶(2021)¡·



05

ÐÂѪ˨ËÄÏ̥ÆÚ²Î¿¼Çø¼ä


Ŀǰ¾ø´óÎÞÊý³¢ÊÔÊÒ¸ø³öµÄÄýѪָ±ê²Î¿¼ÁìÓò¶¼³¤¶ÌÔÐÆÚºÍͨ³£ÈËȺ£¬£¬£¬£¬£¬£¬£¬£¬¶ø»³Ì¥ÆÚÔи¾µÄѪҺÊÇ´¦ÓÚÉúÀíÐԵĸßÄý״̬£¬£¬£¬£¬£¬£¬£¬£¬¹ÊÔи¾²»ÄܲÎÕÕ·Ç»³Ì¥ÈËȺÄýѪָ±êµÄ²Î¿¼Çø¼ä£¬£¬£¬£¬£¬£¬£¬£¬ÔÚ½«ÑªË¨ËÄÏîÖ¸±êÆÕ±éÓÃÓÚ»³Ì¥ÆÚ¼äÓëѪ˨ÐÔ¼²²¡µÄÁÙ´²ÆÀ¹À֮ǰ£¬£¬£¬£¬£¬£¬£¬£¬ÓбØÒªÎª½¡È«Ôвú¸¾³ÉÁ¢²Î¿¼Çø¼ä ¡£¡£¡£¡£¡£±±¾©´óѧµÚÈýÒ½ÔºÕÅæµ¾²µÈ½ÌÔ±ÔÚ¡¶THE JOURNAL OF Obstetrics ancGynaecology Research¡·°ä·¢µÄѧÊõÂÛÎĶÔÖйúÔи¾»³Ì¥ÆÚTAT¡¢TM¡¢t-PAIC¡¢PICµÄ±ä¶¯¼°½¡È«Ôвú¸¾»³Ì¥ÆÚÌØ¶¨²Î¿¼ÁìÓò½øÐÐÁË×êÑÐ ¡£¡£¡£¡£¡£×êÑÐÄÉÈ뻪±±µØÓò190Àý½¡È«Ôвú¸¾£¬£¬£¬£¬£¬£¬£¬£¬Ñ¡È¡»¯Ñ§·¢¹â·¨¼ì²âTAT¡¢TM¡¢t-PAICºÍPICˮƽ£¬£¬£¬£¬£¬£¬£¬£¬ÔÚ2.5%ºÍ97.5%µÄÉ¢²¼ÁìÓò³ÉÁ¢ÁË»³Ì¥ÆÚÌØ¶¨²Î¿¼Çø¼ä£¨Á˾ּû±í2£© ¡£¡£¡£¡£¡£×îÖÕ×êÑÐÅú×¢£¬£¬£¬£¬£¬£¬£¬£¬TAT¡¢TM¡¢t-PAICµÄˮƽ´ÓÔÐÔçÆÚ(»³Ì¥5-12ÖÜ)µ½ÔÐÍíÆÚ(»³Ì¥28-40ÖÜ)ÏÔ×ÅÔö³¤£¬£¬£¬£¬£¬£¬£¬£¬¶øPICµÄˮƽ²¢Ã»ÓÐËæ×ÅÔÐÖܵÄÔö³¤¶ø²úÉúÏÔÖø±ä¶¯ ¡£¡£¡£¡£¡£



×ÛÉÏËùÊö£¬£¬£¬£¬£¬£¬£¬£¬ÐÂѪ˨ËÄÏî±êÖ¾ÎïÏà±È´«Í³ÄýѪËÄÏî¡¢D-Dimer¡¢FDP¸üÔç¡¢¸üÌØÒ죬£¬£¬£¬£¬£¬£¬£¬ÔÚѪ˨ÆðÍ·Ðγɽ׶ξÍÓÐÏÔÖø±ä¶¯£¬£¬£¬£¬£¬£¬£¬£¬ÔÚÔÐÆÚ¡¢²úǰ¡¢²úºó¶¯Ì¬¼ì²âͨÀýÄýѪÏîÖ÷ÕÅͬʱ£¬£¬£¬£¬£¬£¬£¬£¬ÖÜÆÚÐԹ鲢¼à²âTAT¡¢TM¡¢t-PAIC¡¢PICˮƽ¿ÉÄÜÈÃÁÙ´²Ò½Éú¸üÕýÈ·µØÅжÏÔвú¸¾ÊÇ·ñ´æÔÚVTEµÄ·çÏÕ£¬£¬£¬£¬£¬£¬£¬£¬ÊµÏÖ²ú¿ÆVTEÔçÆÚÕï¶Ï¡¢RSAµÈ²ú¿ÆÓйØÑªË¨¼²²¡µÄÔçÆÚ¼ø±ðºÍ¹ýÎÊ£¬£¬£¬£¬£¬£¬£¬£¬´Ó¶ø´ïµ½¸üºÃµÄÔ¤·À±£½¡³ÉЧ ¡£¡£¡£¡£¡£





9001cc½ðɳѪ˨ËÄÏî²úÆ·½éÉÜ


? ²½Öèѧ£º´Å΢Á£»£»£»£»£»¯Ñ§·¢¹â·¨

??Ñù±¾ÀàÐÍ£ºèÛéÚËáÄÆÑª½¬

??У׼ÖʿأºËæºÐÔùËÍ

??ºÏÓûúÐÍ£ºÈ«ÐÂÈý¿îÈ«×Ô¶¯»¯Ñ§·¢¹âÒÇÆ÷ ¡£¡£¡£¡£¡£ÓµÓÐÕ¼µØÓ×£¬£¬£¬£¬£¬£¬£¬£¬²âÊÔËٶȿ죬£¬£¬£¬£¬£¬£¬£¬½Ã½ÝÐԸߵÅ×ÅÊÆ£¬£¬£¬£¬£¬£¬£¬£¬Äܹ»Âú×ã¶àÖÖÖն˿ͻ§ÐèÒª ¡£¡£¡£¡£¡£



²Î¿¼Îļþ

[1]?Say L, Chou D, Gemmill A,et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014 Jun;2(6):e323-33.

[2]?Bourjeily G, Paidas M, Khalil H,et al.Pulmonary embolism in pregnancy. Lancet. 2010 Feb 6; 375(9713): 500-12.

[3]?Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy [J]. Blood Adv, 2018, 2(22): 3317-3359.

[4]?ÍõÓî, ËïÇïèª, ÕÅö©ö©µÈ. TAT¡¢PIC¡¢TM¡¢tPAI-CÔ¤²âÔÐÖÐÍíÆÚÔи¾Éî¾²ÂöѪ˨¼ÛÖµ[J]. Öйú´òËãÉúÓýѧÔÓÖ¾, 2021, 29(01): 79- 83+211.

[5]?Éò„Â, ²ÌºÃºº, ÖìÝíö©. ¾²ÂöѪ½¬ÖÐѪ˨µ÷½Úµ°°×¡¢ÄýѪø-¿¹Äý Ѫø¸´ºÏÎï¡¢×éÖ¯ÐÍÏËÈÜøԭ¼¤»î¼Á-ÒÖÔìÎ︴ºÏÎï¡¢ÏËÈÜø-¿¹ ÏËÈÜø¸´ºÏÎïˮƽ½áºÏCapriniÆÀ·ÖÔ¤²âÆÊ¹¬²úÊõºóÏÂÖ«Éî¾²ÂöѪ˨ÐγɷçÏÕ[J]. ÖйúÐÔ¿ÆÑ§, 2023, 32(03): 75-79.

[6]?¸´·¢ÐÔÁ÷²ú¹é²¢ÑªË¨Ç°×´Ì¬ÕïÖÎÖйúר¼Ò¹²Ê¶.ÖлªÉúÖ³Óë±ÜÔÐÔÓÖ¾ 2021 Äê10 ÔÂµÚ 41 ¾íµÚ 10 ÆÚ 0861-0875.

[7]?Trimester-specific reference intervals of TAT, TM, tPAI-C and PIC for healthy Chinese pregnant women.J. Obstet. Gynaecol. Res. Vol. 47, No. 1: 368¨C374, January 2021

¸ßµÍ»¬¶¯²é¿´ÆëÈ«²Î¿¼Îļþ



END

ÎÄÕÂÆðÔ´£º9001cc½ðɳÉúÎï

Ôð±à£ºEcho

У¶Ô£ºPretty¡¢Miss Jia


 
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿